#United States #San Francisco #Cancer Treatments #Healthcare Conference #Rigel Pharmaceuticals

Rigel Pharmaceuticals at the 43rd Annual J.P. Morgan Healthcare Conference

On January 8, 2025, Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a prominent player in the biotech industry focusing on hematologic disorders and cancer, announced its participation in the upcoming 43rd Annual J.P. Morgan Healthcare Conference. This influential event will take place in San Francisco, California, on Thursday, January 16, 2025, at 8:15 AM PT (11:15 AM ET).

The company's President and CEO, Raul Rodriguez, will present a comprehensive overview of Rigel Pharmaceuticals during the conference. This presentation will highlight the company’s commitment to addressing critical unmet needs in the medical field, particularly in the areas of hematologic disorders and cancer treatments. The conference is renowned for being a key platform where investors and thought leaders in the healthcare industry converge to discuss advancements, trends, and opportunities in the realm of biotechnology and pharmaceuticals.

Participants interested in accessing the live webcast or the archived recording of the presentation can do so by visiting the Investor Relations section on Rigel's official website at www.rigel.com. Attendees are advised to connect to the website ahead of the presentation start time to accommodate any necessary software downloads, ensuring a smooth viewing experience.

About Rigel Pharmaceuticals

Founded in 1996, Rigel Pharmaceuticals, Inc. is dedicated to discovering, developing, and delivering innovative therapies aimed at significantly improving the lives of patients grappling with hematologic disorders and cancer. The company is headquartered in South San Francisco, California, and has established a strong reputation for its pioneering approach to drug development.

Rigel's pipeline of potential products demonstrates its commitment to addressing complex healthcare challenges. The company’s portfolio includes marketed products as well as numerous candidates currently in various stages of clinical development, underscoring its strategic focus on improving therapeutic options for patients.

For more detailed information on Rigel Pharmaceuticals, including their marketed products and research pipeline, industry enthusiasts and investors are encouraged to visit www.rigel.com. Investor relations inquiries can be directed to Rigel Pharmaceuticals at 650-624-1232 or via email.

Media Contact

For media inquiries, David Rosen of Argot Partners is available at 646-461-6387 or via email. Rigel Pharmaceuticals continues to engage with media and investors as it advances its mission to innovate in the biotechnology sector.

Conclusion

The upcoming J.P. Morgan Healthcare Conference is an essential event for Rigel Pharmaceuticals as it highlights the company's ongoing efforts and achievements in the biotech landscape. By presenting a detailed overview, Raul Rodriguez aims to share valuable insights and foster relationships within the investment community, ultimately driving forward Rigel's mission to enhance patient care through novel therapeutic solutions.